Related Experiment Video

Updated: Mar 29, 2026

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

2.4K

Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?

Shikha Satendra Singh1, Wei Ney Yap1, Frank Arfuso1

  • 1Shikha Satendra Singh, Wei Ney Yap, Shreya Kar, Chao Wang, Wanpei Cai, Gautam Sethi, Alan Prem Kumar, Cancer Science Institute of Singapore, National University of Singapore, Singapore City 117597, Singapore.

World Journal of Gastroenterology
|November 26, 2015
PubMed

Insights

The phosphatidylinositol-3 kinases (PI3K)/Akt/mTOR pathway is frequently activated in gastric cancer. Targeting this pathway with inhibitors and using predictive biomarkers can lead to more personalized and effective gastric cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Signaling

Background:

  • The phosphatidylinositol-3 kinases (PI3K)/Akt/mTOR pathway is frequently dysregulated in gastric cancer (GC) due to genetic alterations like PIK3CA mutations or PTEN loss.
  • This dysregulation contributes significantly to gastric oncogenesis, highlighting the need for targeted therapeutic strategies.

Purpose of the Study:

  • To review the common dysregulations of the PI3K/Akt/mTOR pathway in GC.
  • To discuss single and dual pathway inhibitors currently under development for GC treatment.
  • To summarize advancements in predictive biomarkers for personalized therapy.

Main Methods:

  • Literature review of common PI3K/Akt/mTOR pathway dysregulations in GC.
  • Analysis of preclinical and clinical data on PI3K/Akt/mTOR inhibitors for solid tumors, including GC.
  • Summary of recent findings on predictive biomarkers for PI3K/Akt/mTOR targeted therapies.

Main Results:

  • Frequent activation of the PI3K/Akt/mTOR pathway is observed in GC.
  • Various single and dual inhibitors targeting this pathway are in development for GC.
  • Predictive biomarkers are crucial for identifying patients who will benefit from these targeted therapies.

Conclusions:

  • Targeted inhibition of the PI3K/Akt/mTOR pathway holds promise for GC treatment.
  • The development and application of predictive biomarkers are essential for personalized medicine approaches in GC.
  • Combining pathway inhibitors with predictive biomarkers can enhance therapeutic efficacy and specificity in gastric cancer.
Keywords:
EpidemiologyGastric cancerPI3K/Akt/mTOR pathwayPredictive biomarkersTargeted therapy

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.9K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...
15.9K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
19.2K